ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with HER2-low metastatic breast cancer with HR-positive and HR-negative disease – AstraZeneca US


ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with HER2-low metastatic breast cancer with HR-positive and HR-negative disease  AstraZeneca US
source


Leave a Reply

Your email address will not be published.